Aromasin (Exemestane) – Pfizer, 30 tabs per 25 mg

70

Category:

Description

Exemestane is a steroidal Aromatase Inhibitor (AI) that is most commonly known as Aromasin. In fact, the Aromasin brand name is the only pharmaceutical grade brand of the Exemestane AI due to the tight patent Upjohn has maintained on the product. While tightly controlled by the pharmaceutical giant, Aromasin is available in numerous countries around the globe.

Aromasin is officially classified as a steroidal suicide Aromatase Inhibitor, and carries the ability to inhibit the aromatase enzyme, which is responsible for the production or conversion of testosterone to estrogen. Aromasin has the ability to block aromatization, which in turn inhibits the production of estrogen, and thereby lowers the body’s serum estrogen levels. This will prove useful to breast cancer patients as breast cancer often feeds off the estrogen hormone. It will also prove useful to the anabolic steroid user.

Many anabolic steroids have the ability to increase estrogen levels due to the aromatase process, specifically the conversion of testosterone to estrogen. This can lead to gynecomastia and water retention. Excess water retention can also promote high blood pressure when it becomes severe. Steroids that do not carry a strong estrogenic nature can also cause these effects, most notably gynecomastia if they carry a progestin nature. A prime example would be Nandrolone, which while it aromatizes only does so at 20% the rate of testosterone. However, it also carries a strong progestin nature, and progesterone has been well noted for carrying the ability to stimulate the estrogenic mechanism in the mammary tissue. By administering Aromasin during the use of anabolic steroids, this will inhibit the aromatase process, lower estrogen levels and protect the individual from estrogenic side effects. How effective is Aromasin? The product claims on average to have the ability to lower serum estrogen levels by 85%.

Aromasin also has the ability to stimulate natural testosterone production, which is precisely why some will include it during their PCT. Like Arimidex and Letrozole, Aromasin will stimulate the pituitary to release more Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH), two hormones essential to natural testosterone production. While the other common AI’s share this trait, Aromasin has been shown to carry a slight androgenic effect, as well as the ability to increase the production of Insulin-Like Growth Factor-1 (IGF-1). This is a trait no other AI can claim to carry. By using Aromasin during PCT, the individual receives the desired testosterone boost necessary for recovery, but with the IGF-1 increase also creates a stronger anabolic atmosphere. This is deemed useful by some steroid users as it could potentially give them the ability to protect their lean tissue all the more during use. However, when we look at the direct effects of Aromasin as it pertains to PCT, we will find PCT use is normally not recommended despite these positive effects.

In a therapeutic setting, by blocking the aromatase enzyme, Aromasin actively prohibits the cancer from feeding off the hormone necessary to its survival. It has been proven highly effective for this purpose, but only after the use of the Selective Estrogen Receptor Modulator (SERM) Nolvadex (Tamoxifen Citrate) has failed. While effective, it is also not as commonly used as Arimidex for this purpose as Arimidex largely maintains itself as the primary AI in breast cancer treatment not only among post-menopausal women but in a host of breast cancer scenarios.

For more information: https://www.steroid.com/Aromasin.php

About the author